Antiva Biosciences

Antiva Biosciences is pioneering a patient-centric, non-surgical approach to treat oncogenic HPV infection and cervical pre-cancer. Its lead candidate, ABI-2280, is a topical therapy designed for at-home use, addressing a significant unmet need where current standards involve invasive procedures or watchful waiting. The company has advanced into Phase 1b/2 clinical trials and is backed by experienced leadership and life science investors. If successful, Antiva's therapy could transform the management of HPV-related disease, improving access and outcomes for women worldwide.

Proprietary small molecules formulated for topical application to treat HPV infection and related pre-cancerous lesions by targeting localized disease with minimal systemic exposure.

The space for pharmacologic treatment of hrHPV/CIN is nascent but growing. Competitors include companies developing therapeutic vaccines, immune modulators (like Inovio's VGX-3100), and other antiviral approaches. Antiva's topical, small-molecule strategy differentiates it from most injectable or systemically administered candidates.